

## Supporting Information

**Title: A matrix metalloproteinase-activated magnetic resonance imaging and Photoacoustic imaging contrast agent with improved turn-on relaxivity response and anion compatibility**

Tingwei Meng<sup>1,3#</sup>, Bo Fan<sup>2#</sup>, Qian Li<sup>2</sup>, Xiaoyang Peng<sup>1</sup>, Jun Xu<sup>4\*</sup>, Ruiping Zhang<sup>3\*</sup>

1 School of Basic Medical Sciences, Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030001, Shanxi, People's Republic of China

2 Department of Pharmacy, School of Pharmacy, Shanxi Medical University, Taiyuan 030001, Shanxi, People's Republic of China


3 Imaging Department of the Affiliated Bethune Hospital of Shanxi Medical University, Taiyuan 030001, People's Republic of China

4 First Hospital of Shanxi Medical University, Taiyuan 030001, People's Republic of China


# These authors contributed equally to this work

\* Correspondence: Ruiping Zhang, jun Xu


Imaging Department of the Affiliated Bethune Hospital, Shanxi Medical University,  
Email [zrp\\_7142@163.com](mailto:zrp_7142@163.com)




**Fig.S1** Zeta potential of PEG-PepMMP2-MNP-Gd.




**Fig.S2** Stability study of PEG-PepMMP2-MNP-Gd (A) and PEG-MNP-Gd (B) in PBS and FBS over 24 hours




**Fig.S3** Stability of PEG-PepMMP2-MNP-Gd (A) and PEG-MNP-Gd (B) with  $Gd^{3+}$  ions in PBS (pH = 7.4).




**Fig.S4** UV-vis-NIR spectrum of PEG-PepMMP2-MNP-Gd. The nanoprobe exhibited a broad absorbance ranging from UV to NIR wavelengths for its potential application of PAI.



**Fig.S5** The PA spectra of PEG-PepMMP2-MNP-Gd (800  $\mu\text{g/mL}$ ) and the mouse blood.




**Fig.S6** (A) PA images and the quantitative data of 4T1 cells incubation with PEG-PepMMP2-MNP-Gd at various concentrations (0, 50, 100, 200, 400, and 800  $\mu\text{g/mL}$ ). (B) T1-weighted images and MR signal intensity changes of 4T1 cells incubation with PEG-PepMMP2-MNP-Gd at various concentrations (0, 50, 100, 200, 400, and 800  $\mu\text{g/mL}$ ).



**Fig.S7** MR and PA imaging studies of PEG-PepMMP2-MNP-Gd after intratumoral administration. T1-weighted MR axial images of tumor-bearing mice before (Prescan) and at various time points (0 h, 2 h, 4 h, 12h, 24 h) after injection of PEG-PepMMP2-MNP-Gd (A) and PEG-MNP-Gd using 3.0 T clinical MRI equipment (B). PA images in the tumor region collected by MOST imaging system before (Prescan) and at various time points (0 h, 2 h, 4 h, 12h, 24 h) after intratumoral injection of PEG-PepMMP2-MNP-Gd (C) or PEG-MNP-Gd (D). The white circles point the tumor sites. In the image of pre injection, there were little intrinsic contrast between the tumors and surrounding tissue. After 2 hours, a remarkable brightened effect could be clearly detected in the local injection site of tumor in both groups. At 12 h after injection, the

MRI signals and PA signals of active nanoprobe reached a maximum. But in the inactive nanoprobe, the signal intensity diminished quickly within 24 h. The results indicated that the active nanoprobe had a longer residence time signal in tumor tissue as compared with inactive nanoprobe.



**Fig.S8** Blood chemistry indexes (ALT, AST, BUN and SCr) of mice for the control, and 1 d and 7 d after treatment with PEG-PepMMP2-MNP-Gd (A) and PEG-MNP-Gd (B). (C) Complete blood panel indexes of mice after PEG-PepMMP2-MNP-Gd and PEG-MNP-Gd treatments.